TELO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Telomir Pharmaceuticals Inc (TELO.O) is -4.62, compared to its 5-year average forward P/E of -5.83. For a more detailed relative valuation and DCF analysis to assess Telomir Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.83

Current PE

-4.62

Overvalued PE

1.34

Undervalued PE

-13.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4595.74

Current PS

92.14

Overvalued PS

37578.73

Undervalued PS

-28387.25

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TELO News & Events

Events Timeline

No data

News

3.5

01-06Benzinga

Coinbase CEO Armstrong Invests in NewLimit, Secures $45 Million Funding

4.5

2025-10-10NASDAQ.COM

Friday's Underperformers: Pharmaceutical, Oil, and Gas Exploration & Production Shares

4.5

2025-10-07Benzinga

Stock Market Update: Dow Jones and Nasdaq Futures Decline as Trade Deficit Data Release is Postponed Due to Shutdown—Trilogy Metals, AMD, and Applovin Under Scrutiny

People Also Watch

Frequently Asked Questions

What is Telomir Pharmaceuticals Inc (TELO) stock price today?

The current price of TELO is 1.36 USD — it has decreased -4.23 % in the last trading day.

What is Telomir Pharmaceuticals Inc (TELO)'s business?

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

What is the price predicton of TELO Stock?

Wall Street analysts forecast TELO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Telomir Pharmaceuticals Inc (TELO)'s revenue for the last quarter?

Telomir Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Telomir Pharmaceuticals Inc (TELO)'s earnings per share (EPS) for the last quarter?

Telomir Pharmaceuticals Inc. EPS for the last quarter amounts to -0.03 USD, decreased -85.00 % YoY.

What changes have occurred in the market's expectations for Telomir Pharmaceuticals Inc (TELO)'s fundamentals?

The market is revising No Change the revenue expectations for Telomir Pharmaceuticals, Inc. (TELO) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -29.53%.

How many employees does Telomir Pharmaceuticals Inc (TELO). have?

Telomir Pharmaceuticals Inc (TELO) has 0 emplpoyees as of January 09 2026.

What is Telomir Pharmaceuticals Inc (TELO) market cap?

Today TELO has the market capitalization of 48.82M USD.